Anna Krzyczmonik1, Thomas Keller1, Francisco R López-Picón2,3, Sarita Forsback1,4, Anna K Kirjavainen1, Jatta S Takkinen2,3, Aleksandra Wasilewska5, Mika Scheinin6, Merja Haaparanta-Solin2,3, Franciszek Sączewski5, Olof Solin7,8,9. 1. Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland. 2. PET Preclinical Imaging Laboratory, Turku PET Centre, University of Turku, Turku, Finland. 3. MediCity Research Laboratory, University of Turku, Turku, Finland. 4. Department of Chemistry, University of Turku, Turku, Finland. 5. Department of Chemical Technology of Drugs, Faculty of Pharmacy, Medical University of Gdańsk, Gdańsk, Poland. 6. Institute of Biomedicine, University of Turku, and Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland. 7. Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland. olof.solin@abo.fi. 8. Department of Chemistry, University of Turku, Turku, Finland. olof.solin@abo.fi. 9. Accelerator Laboratory, Turku PET Centre, Åbo Akademi University, Kiinamyllynkatu 4-8, FI-20520, Turku, Finland. olof.solin@abo.fi.
Abstract
PURPOSE: The α2-adrenoceptors mediate many effects of norepinephrine and epinephrine, and participate in the regulation of neuronal, endocrine, cardiovascular, vegetative, and metabolic functions. Of the three receptor subtypes, only α2A and α2C are found in the brain in significant amounts. Subtype-selective positron emission tomography (PET) imaging of α2-adrenoceptors has been limited to the α2C subtype. Here, we report the synthesis of 6-[18F]fluoro-marsanidine, a subtype-selective PET tracer candidate for α2A-adrenoceptors, and its preclinical evaluation in rats and mice. PROCEDURES: 6-[18F]Fluoro-marsanidine was synthesized using electrophilic F-18 fluorination with [18F]Selectfluor bis(triflate). The tracer was evaluated in Sprague Dawley rats and in α2A-knockout (KO) and wild-type (WT) mice for subtype selectivity. In vivo PET imaging and ex vivo brain autoradiography were performed to determine the tracer distribution in the brain. The specificity of the tracer for the target was determined by pretreatment with the subtype-non-selective α2-agonist medetomidine. The peripheral biodistribution and extent of metabolism of 6-[18F]fluoro-marsanidine were also analyzed. RESULTS: 6-[18F]Fluoro-marsanidine was synthesized with [18F]Selectfluor bis(triflate) in a radiochemical yield of 6.4 ± 1.7 %. The molar activity was 3.1 to 26.6 GBq/μmol, and the radiochemical purity was > 99 %. In vivo studies in mice revealed lower uptake in the brains of α2A-KO mice compared to WT mice. The results for selectivity were confirmed by ex vivo brain autoradiography. Blocking studies revealed reduced uptake in α2A-adrenoceptor-rich brain regions in pretreated animals, demonstrating the specificity of the tracer. Metabolite analyses revealed very rapid metabolism of 6-[18F]fluoro-marsanidine with blood-brain barrier-permeable metabolites in both rats and mice. CONCLUSION: 6-[18F]Fluoro-marsanidine was synthesized and evaluated as a PET tracer candidate for brain α2A-adrenoceptors. However, rapid metabolism, extensive presence of labeled metabolites in the brain, and high non-specific uptake in mouse and rat brain make 6-[18F]fluoro-marsanidine unsuitable for α2A-adrenoceptor targeting in rodents in vivo.
PURPOSE: The α2-adrenoceptors mediate many effects of norepinephrine and epinephrine, and participate in the regulation of neuronal, endocrine, cardiovascular, vegetative, and metabolic functions. Of the three receptor subtypes, only α2A and α2C are found in the brain in significant amounts. Subtype-selective positron emission tomography (PET) imaging of α2-adrenoceptors has been limited to the α2C subtype. Here, we report the synthesis of 6-[18F]fluoro-marsanidine, a subtype-selective PET tracer candidate for α2A-adrenoceptors, and its preclinical evaluation in rats and mice. PROCEDURES: 6-[18F]Fluoro-marsanidine was synthesized using electrophilic F-18 fluorination with [18F]Selectfluor bis(triflate). The tracer was evaluated in Sprague Dawley rats and in α2A-knockout (KO) and wild-type (WT) mice for subtype selectivity. In vivo PET imaging and ex vivo brain autoradiography were performed to determine the tracer distribution in the brain. The specificity of the tracer for the target was determined by pretreatment with the subtype-non-selective α2-agonist medetomidine. The peripheral biodistribution and extent of metabolism of 6-[18F]fluoro-marsanidine were also analyzed. RESULTS:6-[18F]Fluoro-marsanidine was synthesized with [18F]Selectfluor bis(triflate) in a radiochemical yield of 6.4 ± 1.7 %. The molar activity was 3.1 to 26.6 GBq/μmol, and the radiochemical purity was > 99 %. In vivo studies in mice revealed lower uptake in the brains of α2A-KO mice compared to WT mice. The results for selectivity were confirmed by ex vivo brain autoradiography. Blocking studies revealed reduced uptake in α2A-adrenoceptor-rich brain regions in pretreated animals, demonstrating the specificity of the tracer. Metabolite analyses revealed very rapid metabolism of 6-[18F]fluoro-marsanidine with blood-brain barrier-permeable metabolites in both rats and mice. CONCLUSION:6-[18F]Fluoro-marsanidine was synthesized and evaluated as a PET tracer candidate for brain α2A-adrenoceptors. However, rapid metabolism, extensive presence of labeled metabolites in the brain, and high non-specific uptake in mouse and rat brain make 6-[18F]fluoro-marsanidine unsuitable for α2A-adrenoceptor targeting in rodents in vivo.
Authors: Jaya Prabhakaran; Vattoly J Majo; Matthew S Milak; Pratap Mali; Lyudmila Savenkova; J John Mann; Ramin V Parsey; J S Dileep Kumar Journal: Bioorg Med Chem Lett Date: 2010-05-22 Impact factor: 2.823
Authors: Jussi Lehto; Jere R Virta; Vesa Oikonen; Anne Roivainen; Pauliina Luoto; Eveliina Arponen; Semi Helin; Johanna Hietamäki; Aila Holopainen; Marita Kailajärvi; Juha M Peltonen; Juha Rouru; Jukka Sallinen; Kirsi Virtanen; Iina Volanen; Mika Scheinin; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2014-09-09 Impact factor: 9.236
Authors: S P Hume; E Hirani; J Opacka-Juffry; S Osman; R Myers; R N Gunn; J A McCarron; R D Clark; J Melichar; D J Nutt; V W Pike Journal: Eur J Nucl Med Date: 2000-05
Authors: Franciszek Saczewski; Anita Kornicka; Apolonia Rybczyńska; Alan L Hudson; Shu Sean Miao; Maria Gdaniec; Konrad Boblewski; Artur Lehmann Journal: J Med Chem Date: 2008-06-03 Impact factor: 7.446
Authors: Aleksandra Wasilewska; Franciszek Sączewski; Alan L Hudson; Mehnaz Ferdousi; Mika Scheinin; Jonne M Laurila; Apolonia Rybczyńska; Konrad Boblewski; Artur Lehmann Journal: Eur J Med Chem Date: 2014-09-28 Impact factor: 6.514